Ataraxis

Company profile

About Ataraxis

Ataraxis is a clinical AI company pioneering precision medicine through advanced artificial intelligence methods applied to multi-modal medical data. The company's mission is to completely personalize cancer treatment by predicting patient outcomes and treatment response at the individual level. Ataraxis develops AI foundation models, including their proprietary Falcon model trained on hundreds of millions of pan-cancer pathology slide images, that extract novel clinical, morphological, and molecular features beyond what single data types can reveal. Their flagship platform, Ataraxis Breast, offers clinically validated prognostic and predictive tools for breast cancer, including recurrence risk assessment, chemotherapy benefit prediction, and neoadjuvant therapy response prediction. Unlike traditional molecular genomic tests, Ataraxis delivers results within 24 hours without exhausting physical tissue samples. The company's proprietary Ataraxis Tau framework uses causal inference methods to estimate individualized treatment effects from real-world data, moving beyond population-level predictions to provide personalized treatment benefit assessments. Ataraxis actively collaborates with top international cancer centers and health systems on development, validation, and clinical implementation of their technology, with peer-reviewed publications in Nature Communications and presentations at major oncology conferences including ASCO, SABCS, and ESMO.

Company description · Ataraxis official website